Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / SCGB2A1

SCGB2A1

Basics

Aliases:
This biomarker is also known as:
  • mammaglobin-2,
  • mammaglobin-B,
  • LIPHC,
  • MGB2,
  • mammaglobin B,
  • lacryglobin,
  • mammaglobin 2,
  • UGB3,
  • Lacryglobin,
  • Secretoglobin family 2A member 1,
  • Lipophilin-C,
  • O75556,
  • lipophilin-C,
  • secretoglobin, family 2A, member 1,
  • lipophilin C,
  • LPHC,
  • Mammaglobin-2,
  • MGC71973,

View in BioMuta

Description…

SCGB2A1, also known as MGB2 or mammaglobin B, encodes a small secreted protein from the secretoglobin family, part of the uterglobin superfamily. SCGB2A1 is normally expressed in the thymus, trachea, kidney, steroid responsive tissues (prostate, testis, uterus, breast and ovary) and salivary gland.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: SCGB2A1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

SCGB2A1, also known as MGB2 or mammaglobin B, is highly homologous to mammaglobin A (MGB1), which is overexpressed in breast cancer. SCGB2A1 has also been found to be overexpressed in primary breast cancers. Recently SCGB2A1 was found to be a top differentially expressed gene in ovarian cancer.

Performance Comment

SCGB2A1 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. SCGB2A1 was not in the group of 13 selected for further validation.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.